Form 10-Q PMV Pharmaceuticals, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Oppenheimer Upgrades PMV Pharmaceuticals Inc. (PMVP) to Outperform
November 8, 2024 6:04 AM ESTOppenheimer analyst Jeff Jones upgraded PMV Pharmaceuticals Inc. (NASDAQ: PMVP) from Perform to Outperform with a price target of $6.00.
The analyst comments "On Thursday, PMV Pharmaceuticals reported 3Q results and provided a business update. The Phase 2/pivotal monotherapy trial for rezatapopt remains on... More
